“Merck is currently supplying key products and services to over 45 COVID-19 vaccine programmes around the world”
BioSpectrum Asia|June 2020
Asia Pacific Life Science business of Merck develops improved and enhanced technologies from biopharmaceutical therapies to cutting-edge systems for scientific research and production. Responding to COVID-19 outbreak, Merck’s BioProcessing unit is engaged in consolidating and supplying raw materials along with characterization and detection of vaccine research products. Merck actively evaluates and leverages business continuity plans for COVID-19 vaccines and therapies development. Merck’s SARS-CoV-2 detection, characterization, vaccine and therapy production capabilities are leveraged at the Jenner Institute for the development of Oxford vaccine. Prioritizing on crucial timeline Merck’s advanced upstream and downstream portfolios target faster yield and productivity to support and expedite the need of an hour. BioSpectrum Asia spoke with Benoit Opsomer, Vice President & Head of BioProcessing, Asia Pacific, Life Science business at Mercato explore the company’s commitment towards researchers, developers and manufacturers to combat COVID-19 pandemic.
Hithaishi C Bhaskar
“Merck is currently supplying key products and services to over 45 COVID-19 vaccine programmes around the world”

Benoit Opsomer, Vice President & Head of BioProcessing, Asia Pacific, Merck Pte. Ltd, Singapore

How do you describe the crucial steps and measures in COVID-19 vaccine development?

A major factor that contributed to the acceleration of vaccine development for the SARS-CoV-2 virus (COVID-19) has been the early and speedy identification of the novel coronavirus’ genome sequencing, which contributed to an array of vaccination and treatment development efforts around the world.

Diagnostic tests play a critical role in the global effort to contain and fight the virus. These tests help physicians determine the presence or absence of a disease in patients, and their findings are crucial to making treatment decisions. The spread of COVID-19 has demonstrated the importance of diagnostics and will have a lasting impact on a national and global level, reshaping how governments and healthcare players deal with future pandemics.

With the global population exceeding 7.5 billion, vaccine developers require unprecedented capabilities for large-scale production of any approved therapies to meet the demand.

While we don’t produce vaccines ourselves, Merck has over four decades of experience in supporting customers in vaccine development and manufacturing, which is being leveraged during this critical time. Our biggest value add is our experience, not just in terms of routine business operations, but as a reliable and agile technology partner.

Can you elaborate on the significant role Merck is playing at the Jenner Institute and the wider vaccine development ecosystem?

This story is from the June 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the June 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024
Why Singapore is Deep Tech Innovation Frontrunner
BioSpectrum Asia

Why Singapore is Deep Tech Innovation Frontrunner

Move over Artificial Intelligence Al) and Machine Learning ML), there's a new technology on the block Deep Tech. This latest technology holds immense potential for the life sciences industry, and Singapore is leaving no stone unturned in becoming a deep tech hub. From strategic investments to collaborative initiatives and a supportive regulatory environment, read on to find out about the country's initiatives in becoming a deep tech superpower.

time-read
4 mins  |
March 2024
Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?
BioSpectrum Asia

Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?

The World Health Organization (WHO) has taken a significant stride in the battle against Tuberculosis (TB) by introducing shorter drug regimens, aiming to curb a disease that claims countless lives globally. This innovative approach addresses the urgent need for more efficient treatments, especially in regions where TB's toll is highest. With traditional therapies often posing risks to liver health, these shortened regimens offer hope, minimising such concerns while enhancing treatment adherence.

time-read
5 mins  |
March 2024
How pharma is finally researching issues that primarily affect women
BioSpectrum Asia

How pharma is finally researching issues that primarily affect women

Pharma is now concentrating on problems that impact women. Female participation will now directly contribute to cures for diseases that affect them, since more studies specifically targeted at women are planned.

time-read
8 mins  |
March 2024
Championing PAY PARITY
BioSpectrum Asia

Championing PAY PARITY

Despite women's significant strides and contributions in the healthcare field, they are paid less than men. Unfortunately, as is the case in most spheres, persistent pay disparities plague the life sciences sector. How big is the gender pay gap in the pharma industry? Are companies and the industry doing enough to address this issue? Let's find out.

time-read
6 mins  |
March 2024
ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
BioSpectrum Asia

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES

Globally, women constitute 46 per cent of the workforce in the public sector, whereas in the private sector, they represent 33 per cent. The public sector maintains a higher representation of women as employees compared to the private sector as per data from the World Bank.

time-read
10+ mins  |
March 2024
US FDA approves first medication to treat severe frostbite
BioSpectrum Asia

US FDA approves first medication to treat severe frostbite

The US Food and Drug Administration (FDA) has approved Eicos Sciences Inc’s Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

time-read
1 min  |
March 2024
Japanese startup RevolKa to create highly functional proteins by using AI-driven platform
BioSpectrum Asia

Japanese startup RevolKa to create highly functional proteins by using AI-driven platform

RevolKa, a venture-backed biotech startup providing a gamechanging protein engineering technology platform, based in Japan, has signed a contract research agreement with Sekisui Chemical.

time-read
1 min  |
March 2024
Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development
BioSpectrum Asia

Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development

Taiwan-based startup Anbogen Therapeutics, a clinical-stage biotechnology company specialising in groundbreaking cancer drug development, has announced the successful completion of its Series A funding round.

time-read
1 min  |
March 2024
Samsung Biologics & LegoChem Biosciences team up for ADC development
BioSpectrum Asia

Samsung Biologics & LegoChem Biosciences team up for ADC development

South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has signed a partnership agreement with LegoChem Biosciences, a Korean biotech company pioneering the research and development of antibody-drug conjugate (ADC) programmes.

time-read
1 min  |
March 2024